Targeting triple-negative breast cancer: A clinical perspective

Area of Science:

• Oncology
• Genetics

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
• TNBC accounts for 10-15% of breast cancer cases, representing a significant unmet medical need.
• Historically, chemotherapy was the sole systemic treatment for TNBC.

Purpose of the Study:

• To provide an updated overview of current and investigational treatment options for TNBC.
• To discuss the heterogeneity of TNBC and its evolving classification.
• To highlight advancements in therapeutic strategies beyond traditional chemotherapy.

Main Methods:

• Review of existing literature on TNBC classification and treatment modalities.
• Analysis of mRNA expression data for TNBC subtyping (Lehman et al., 2011).
• Incorporation of recent findings on TNBC subtype revisions based on tumor-infiltrating lymphocytes and stromal cell infiltration.

Main Results:

• TNBC classification has evolved from six subtypes to four: basal 1, basal 2, luminal androgen receptor (LAR), and mesenchymal.
• New treatment strategies including immunotherapy, antibody drug conjugates, novel chemotherapy agents, and targeted therapies are under investigation.
• Significant progress has been made in developing alternative treatment options for TNBC.

Conclusions:

• TNBC is a heterogeneous disease requiring diverse therapeutic approaches.
• Emerging treatments offer new hope for patients with TNBC.
• Continued research is crucial for optimizing TNBC management.